Therapeutic banner
Therapeutic banner

Transthyretin (ATTR) Amyloidosis

View the latest scientific data presented at congress events in the past 2 years and discover peer-reviewed publications related to ATTR Amyloidosis.
The information on this page pertains to select congress and publication resources. It is not intended to serve as a comprehensive list of all congress and publications resources.

Explore Therapeutic Areas

Congresses

View More Arrow
Congress-ISPOR-Mobile

Transthyretin Amyloidosis (ATTR)

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2025

November 9-12, 2025 UK

View Details
Congress-AHA-thumbnail

Transthyretin Amyloidosis (ATTR), Cardiovascular (CV)

American Heart Association (AHA) 2025

November 7-10, 2025 USA

View Details
Congress-HFSA-Mobile

Transthyretin Amyloidosis (ATTR)

Heart Failure Society of America (HFSA) 2025

September 26-29, 2025 USA

View Details
Congress-EU-ATTR-Mobile

Transthyretin Amyloidosis (ATTR)

European ATTR Amyloidosis Meeting (EU-ATTR) 2025

September 25-26, 2025 ITALY

View Details
Congress-CAPT-Mobile

Transthyretin Amyloidosis (ATTR)

Canadian Association for Population Therapeutics (CAPT) 2025

September 22-23, 2025 CANADA

View Details
Congress-ESC-Mobile

Transthyretin Amyloidosis (ATTR), Cardiovascular (CV)

European Society of Cardiology (ESC) 2025

August 29 - September 1, 2025 SPAIN

View Details

Publications

View More Arrow

Transthyretin Amyloidosis (ATTR)

Long-term efficacy and safety of vutrisiran in hereditary transthyretin amyloidosis with polyneuropathy: final analysis of the HELIOS-A randomized treatment extension

Amyloid

Author(s)

Cécile Cauquil, David Adams, Julian Gillmore, et al

June 2026

Transthyretin Amyloidosis (ATTR)

Vutrisiran-Mediated Knockdown of Transthyretin in Patients with ATTR Amyloidosis

Clinical Pharmacokinetics

Author(s)

Marianna Fontana, Vincent Algalarrondo, Pablo Garcia-Pavia, et al

May 2026

Transthyretin Amyloidosis (ATTR)

Vutrisiran in East Asian Patients With Transthyretin Amyloidosis With Cardiomyopathy: Post-Hoc Analysis of HELIOS-B

JACC: Asia

Author(s)

Jin Endo, Tetsuo Minamino, Jaewon Oh, et al

May 2026

Transthyretin Amyloidosis (ATTR)

Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy and Renal Impairment: Analyses From HELIOS-B

Journal of Cardiac Failure

Author(s)

Farooq H. Sheikh, Julien Dang, Marianna Fontana, et al

May 2026

Transthyretin Amyloidosis (ATTR)

Best Practices and Key Barriers for Amyloidosis Patient Care at US Specialized Amyloidosis Centers: An Analysis by ARC-ASPIRE

Clinical Medicine Insights: Cardiology

Author(s)

Jose Nativi-Nicolau, Johana Fajardo, Alyssa Galloway, et al

April 2026

Transthyretin Amyloidosis (ATTR)

Effect of vutrisiran on components of health status in transthyretin amyloidosis with cardiomyopathy: the HELIOS-B study

European Journal of Heart Failure

Author(s)

Yasuhiro Hamatani, Brian L Claggett, Muthiah Vaduganathan, et al

March 2026